摘要
目的探讨瘦体合剂对单纯性肥胖并高胰岛素血症患儿的疗效和对相关指标的影响。方法单纯性肥胖并高胰岛素血症患儿43例随机分成瘦体合剂治疗组、二甲双胍治疗对照组。观测治疗前后体脂、血脂、胰岛索抵抗指数等指标。结果治疗后两组体质量、体质量指数、体脂含量、血脂、瘦素、肿瘤坏死因子-α(TNF-α)、空腹血胰岛素、胰岛素抵抗指数均明显降低;近期疗效治疗组显效、有效及总有效率分别为22.7%、59.1%、81.8%,对照组分别为9.5%、52.4%、61.9%,治疗组显著优于对照组;瘦体合剂短期服用未出现明显不良反应。结论瘦体合剂治疗单纯性肥胖并高胰岛素血症总体疗效明显优于对照组,其机制是通过调节脂质代谢、降低TNF-α瘦素水平以改善胰岛素抵抗实现。
Objective To study the clinical therapeutic effectiveness and the mechanism of Shouti Oral Liquid on simple obesity children with hyperinsulinism. Methods Fourty - three patients were divided randomly into the treatment group （TG） and the control group （CG）. TG took Sbouti Oral Liquid and CG took metformin. The course of therapy lasted 6 months. The plasma lipid, body fats, insulin resistance index （IR） and some bormones related to obesity before and after therapy were measured and the changes were analyzed. Results The weight, F%, body mars index （ BMI ）, leptin （LP）, tumor necrosing factor （ TNF - α ）, FINS, IR all declined markedly than pre- therapy in both groups. The significant effect, normal effect and total efficiency were 22.7 %, 59.1%,81.8% respectively in TG and 9.5% ,52.4% ,61.9% in CG. The effect in TG was better than that in CG. A short course with Sbouti Oral Liquid therapy did not have obvious side effect. Conclusions There are lipid metabolism disorder, insulin resistance and high lever LP and TNF- α obesity children with hyperinsulinism. The total effect with Shouti Oral Liquid is better than that with medicine in the control group and the mechanism was regulating lipid metabolism, decreasing LP and TNF- α and ameliorating insulin resistance.
出处
《实用儿科临床杂志》
CAS
CSCD
北大核心
2005年第6期584-586,共3页
Journal of Applied Clinical Pediatrics
基金
武汉市卫生局科研基金项目资助(武卫2002219号)
